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Abstract
Background: Phthalate esters like n-butyl benzyl phthalate (BBP) are widely used plasticizers. BBP
has shown endocrine-disrupting properties, thus having a potential effect on hormone-sensitive
tissues. The aim of this study is to determine the effect of neonatal/prepubertal exposure (post-
natal days 2–20) to BBP on maturation parameters and on the morphology, proliferative index and
genomic signature of the rat mammary gland at different ages of development (21, 35, 50 and 100
days).
Results: Here we show that exposure to BBP increased the uterine weight/body weight ratio at
21 days and decreased the body weight at time of vaginal opening. BBP did not induce significant
changes on the morphology of the mammary gland, but increased proliferative index in terminal
end buds at 35 days and in lobules 1 at several ages. Moreover, BBP had an effect on the genomic
profile of the mammary gland mainly at the end of the exposure (21 days), becoming less prominent
thereafter. By this age a significant number of genes related to proliferation and differentiation,
communication and signal transduction were up-regulated in the glands of the exposed animals.
Conclusion: These results suggest that BBP has an effect in the gene expression profile of the
mammary gland.
Background
Butyl benzyl phthalate (BBP) is a plasticizer commonly
used in pipes, vinyl floor tiles, vinyl foams, and carpet
backing, and to a minor extent, in cellulose plastics and
polyurethane [1]. This compound has shown to be weakly
estrogenic [2], and to induce adverse effects on the devel-
opment of male reproductive system [3-5], thus acting as
an endocrine disruptor. Adult BBP intake has been esti-
mated at 2 µg/kg body weight/day and it has been stated
that exposure to infants and children could be up to three-
fold higher [1]. Environmental endocrine disruptors are
of growing concern due to the potential impact on human
health. Actually, BBP is one of the phthalates selected by
the National Toxicology Program (NTP) Center for the
Evaluation of Risks to Human Reproduction (CERHR),
because of its high production volume, potential for
human exposure from their widespread use and occur-
rence within the environment, concern to the public, and
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icity [6]. The evaluation concluded that there was negligi-
ble concern for adverse reproductive effects in exposed
men, but data was insufficient to reach conclusions on
possible reproductive effects in exposed women [6]. Nev-
ertheless, the European Commission has banned BBP
from toys and child care items at concentrations of greater
than 0,1% by mass of the plasticized material [7] and new
data is providing demonstration of possible developmen-
tal effects in humans [8]. Urinary concentrations of phtha-
late metabolites in pregnant mothers, including the major
BBP metabolite monobenzyl phthalate, have been
inversely correlated to anogenital distance among male
infants [8]. Moreover an etiological association of serum
BBP concentration with endometriosis has been sug-
gested, as severity of endometriosis was strongly corre-
lated with BBP concentration in blood [9]. Although more
data is needed regarding the possible effects of this com-
pound on human health, experimental studies have given
evidence of an antiandrogenic effect of BBP and
monobenzyl phthalate. Prenatal and prepubertal expo-
sure of rats to such compounds induced significant alter-
ations on reproductive system of males, like undescended
testes, decrease in the anogenital distance and other mal-
formations of the external genitalia, sex accessory glands,
epididymis and testes [3-5]. It has also been reported a
decrease in the weight of the ovaries in females exposed
during adulthood, as well as changes in the offspring of
exposed rats, including a decrease of the body weight of
male and female at birth and an increase in the anogenital
distance in females [10]. All these changes are compatible
with an endocrine disrupting action of BBP.
Endocrine disruptors have also been suggested to contrib-
ute to the development of hormone-dependent cancers
[11]. Although the risk for cancer is multifactorial, there is
substantial contribution of environmental factors, includ-
ing diet and environmental chemicals. Breast cancer is an
estrogen-dependent malignancy with a significant mortal-
ity in women worldwide [12]. Changes in the hormonal
environment during critical stages of development can
modify the architecture and biological characteristics of
the mammary gland and thus affect the future susceptibil-
ity to develop breast cancer [13,14]. The effects of envi-
ronmental endocrine disruptors seem to be dependent on
the time when the exposure occurs. Diethylstilbestrol has
been associated to increased or decreased susceptibility
for chemically-induced mammary cancer in rats depend-
ing on the period of exposure [15,16].
The present study is designed to determine the effects of
neonatal and prepubertal exposure to BBP on rat mam-
mary gland at different stages of development using mor-
phological parameters of gland differentiation [13,14],
proliferative index and the genomic expression profile.
Here we report that BBP has an effect on the gene expres-
sion profile of the mammary gland.
Results
Maturation parameters
Neonatal/prepubertal exposure to BBP did not affect body
weight, uterine weight or day at vaginal opening. The uter-
ine to body weight ratios were significantly increased in
the exposed animals at 21 days of age (Table 1). BBP expo-
sure did not modify the day at vaginal opening (control
Table 1: Parameters for post-natal maturation and development
21 days 35 days 50 days 100 days
Uterine weight (mg)
Control 30.0 ± 1.4 167 ± 27 288 ± 17 409 ± 20
BBP 36.0 ± 2.1 207 ± 16 319 ± 24 429 ± 19
Uterine weight/BW (mg/g)
Control 0.51 ± 0.03 1.27 ± 0.20 1.48 ± 0.08 1.31 ± 0.07
BBP 0.65 ± 0.04* 1.56 ± 0.13 1.65 ± 0.10 1.39 ± 0.04
Development of the mammary gland
Number of TEB
Control 39.5 ± 2.32 30.4 ± 5.22 18.3 ± 3.71 0.22 ± 0.22
BBP 40.0 ± 4.68 30.2 ± 5.78 22.7 ± 3.16 0.40 ± 0.40
Number of TD
Control 24.5 ± 1.65 38.2 ± 4.17 41.1 ± 3.40 57.3 ± 5.21
BBP 25.9 ± 2.52 33.5 ± 4.08 46.6 ± 7.31 61.8 ± 5.41
Number of AB
Control 8.0 ± 1.87 14.9 ± 1.08 10.1 ± 2.04 0.2 ± 0.22
BBP 5.7 ± 1.20 13.7 ± 1.65 8.9 ± 1.05 0.2 ± 0.20
Number of Lob1
Control 0 30.1 ± 4.58 43.4 ± 5.74 42.7 ± 6.41
BBP 0 39.0 ± 7.29 42.9 ± 4.43 46.2 ± 8.64
Maturation parameters and histoarchitectural study of the mammary gland for controls and rats exposed neonatally/prepubertally to BBP. Results 
are indicated as mean ± SEM. BW: body weight. *: significantly different compared to control group (p < 0.05).Page 2 of 12
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but decreased significantly (p < 0.05) the body weight at
that day (control group: 101.96 ± 1.09 g; BBP group:
97.26 ± 1.49 g).
Mammary gland architecture
Histoarchitectural analysis of the mammary gland was
performed by determining the number of specific epithe-
lial structures at 21, 35, 50 and 100 days. The number of
undifferentiated TEB decreased from 21 to 100 days in
both control and BBP treated animals, while the TDs and
Lob1 increased over time. Neonatal/prepubertal exposure
to BBP did not modify significantly the number of these
epithelial structures when compared to control groups
(Table 1).
Proliferative index of the mammary gland
BrdU incorporation into the DNA was used as an index of
cell proliferation (Figure 1). TEB from BBP exposed rats
had significantly (p < 0.05) higher proliferation index
than controls by 35 days, whereas in TD and AB the differ-
ences were not significant. The proliferative index of Lob1
from controls increased from 35 to 50 days and decreased
at 100 days, while in BBP exposed rats this structure
showed maximum index of proliferation at 35 days and
decreased thereafter, showing significant differences when
compared to controls at all these ages (Figure 1).
Gene expression analysis by microarrays
Neonatal/prepubertal exposure to BBP induced changes
in the gene expression pattern of the mammary gland
mainly by 21 days, just after the end of the treatment, and
the number of modulated genes was low thereafter (Fig-
ure 2). In 21 days-old rats, BBP exposure resulted in the
up-regulation of 515 genes, 141 of which were known,
and included genes related to morphogenesis and cell dif-
ferentiation, transcription factors, cell proliferation,
response to stress, signal transduction, metabolism, trans-
port and cell organization (Table 2). There was only one
down-regulated gene (gad1). At 35 days of age the number
Proliferative index analyses of the mammary glandFigure 1
Proliferative index analyses of the mammary gland. A: Immunohistochemical detection of BrdU incorporation in prolif-
erating cells (brown cells) in the epithelial structures TEB, TD and ducts, AB and Lob1. Olympus BX40 microscope with 40× 
objective. B: Proliferative index (mean ± SEM) in each epithelial structure at 21, 35, 50 and 100 days of age. *: significantly dif-
ferent compared to control group (p < 0.05).
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unknown; two genes were down-regulated (one known -
gad1-). By 50 days of age, 25 genes were up-regulated (10
known), and 14 genes were down-regulated (eight
known). In the 100 day-old group, two known and one
unknown genes were up-modulated (Table 2).
Functional analysis of the genes found up-regulated in 21
days-old rats showed some categories that were signifi-
cantly (p < 0.05) over-represented: cell proliferation and
differentiation, signal transduction (TGF-beta signaling
pathway, metabotropic glutamate receptor group I path-
way, PI3 kinase pathway, endothelin signaling pathway
and interleukin signaling pathway) and cell communica-
tion, (neuronal activities, anterior/posterior patterning).
We also found over-representation of genes coding for
cytoskeletal proteins among the down-modulated by 50
days.
Validation of microarrays by real time RT-PCR
To validate the results from microarrays we have chosen
several genes that were differentially expressed in the
mammary glands from BBP treated rats: transcription fac-
tors related to proliferation and differentiation (Foxg1,
Hfh1, Nfyc, Ahr, Wt1, Tsn), other genes related to differ-
entiation (Fabp3), adhesion (Cdh8) and communication
(Gad1). We analyzed the gene expression of those genes
by real time RT-PCR. Results of the validation are shown
in Figure 3. In the BBP exposed animals Foxg1, Hfh1, Nfyc
and Ahr were between 1.6- and 2-fold up-regulated in
comparison to their gene expression in untreated animals.
These differences, although discrete, were statistically sig-
nificant for Hfh1 and Ahr, and close to significance for the
other genes. We also obtained statistically significant
increases in the expression of Fabp3, Wt1 and Cadh8. By
35 and 50 days, BBP exposure induced a significant
decrease in the expression of Gad1. The decrease of this
gene found by microarrays at 21 days as well as the
increase in Tsn observed by 100 days of age was not con-
firmed by real time PCR.
Discussion
The objective of the present study was to investigate the
effects of neonatal/prepubertal exposure to BBP in the rat
mammary gland at different times of development. We
have characterized the genomic signature of the mam-
mary gland, observing modifications in the gene expres-
sion profile mainly at the end of the exposure and fewer
changes thereafter. We also studied maturation parame-
ters, finding also alterations compatible with a transitory
effect of this environmental compound.
Although it is difficult to determine doses for experimen-
tal studies, the dose chosen for this study was based on the
work of Singletary et al. [17], where they reported that
treatment of female rats with BBP for 7 days prior to dos-
ing with DMBA decreased mammary tumor incidence by
37%. The number of palpable tumors per rat at week 15
was significantly inhibited by 58% and 71% for animals
administered BBP at 250 and 500 mg/kg, respectively,
compared to controls. Our goal was to determine if neo-
natal and prepubertal only exposure to BBP would have a
direct effect at day 21 and if this treatment would leave
permanent alterations on mammary gland maturation,
cell proliferation and gene expression at later time points.
The offspring were exposed to the BBP via the mother's
milk. Considering that the lactating dams were treated
with 500 mg BBP/kg BW and this is dissipated in the
mother before it makes its way via the milk to the 10 off-
spring, hence it is estimated that they receive 1/100 to 1/
1000 of the mother's dose, i.e. 0,5–5 mg BBP/kg BW/day.
This approximation places the rat BBP exposure near the
EPA safe dose for humans of 0.2 mg/kg/day [18] and sim-
ilar to a 2 µg/kg BW/day for adults, and lower than esti-
mated exposure to infants and children (6 µg/kg BW/day)
[1].
Neonatal/prepubertal exposure to BBP increased the rela-
tive uterine weight at 21 days but not thereafter, and
decreased the body weight at day of vaginal opening
(approximately day 30). In the literature there are con-
flicting results regarding the effect of BBP because it
showed estrogenic effects in vitro but did not modify the
estrogen-modulated gene calbindin-D9k in vivo [19].
However, BBP has also shown to increase the expression
of progesterone receptor mRNA, a gene regulated by estro-
Genomic changes induced by BBPFigure 2
Genomic changes induced by BBP. Number of differen-
tially expressed genes in the mammary glands of rats exposed 
neonatally/prepubertally to BBP when compared to controls 
at different ages. Genes were obtained by confident analysis 
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Gene name Symbol Fold change BBP/Control Gene ID
21 days
Up-regulated genes
Morphogenesis, organogenesis and cell differentiation
Cadherin 1 Cdh1 2.21 NM_031334
Cadherin EGF LAG seven-pass G-type receptor 3 Celsr3 2.16 NM_031320
Cardiotrophin 1 Ctf1 1.98 NM_017129
Early growth response 2 Egr2 2.03 NM_053633
Endothelial cell-specific molecule 1 Esm1 1.91 NM_022604
Forkhead box G1 Foxg1 2.21 NM_012560
Gamma-aminobutyric acid (GABA) B receptor 1 Gabbr1 2.14 AA817879
Glutamate receptor, metabotropic 5 Grm5 2.52 NM_017012
Glypican 2 (cerebroglycan) Gpc2 1.83 NM_138511
NAD(P)H dehydrogenase, quinone 2 Nqo2 1.94 AW918463
Odd Oz/ten-m homolog 2 (Drosophila) Odz2 2.15 NM_020088
Parathyroid hormone-like peptide Pthlh 2.03 NM_012636
Pregnancy-induced growth inhibitor Okl38 2.29 NM_138504
RAS-like family 11 member B Rasl11b 1.96 BQ202027
Tenascin R Tnr 1.93 NM_013045
Wilms tumor 1 Wt1 2.77 NM_031534
Other transcription factors
CUG triplet repeat, RNA-binding protein 2 Cugbp2 2.00 BE112513
Forkhead box A1 (Hnf3a) Foxa1 2.24 NM_012742
HNF-3/forkhead homolog-1 (Hfh1) Hfh1 2.08 NM_022858
Jun dimerization protein 2 Jundp2 2.05 NM_053894
Nuclear transcription factor-Y gamma Nfyc 2.26 NM_012866
TEA domain family member 2 Tead2 1.87 AI043589
Transcription elongation factor A (SII), 2 Tcea2 1.99 NM_057098
Transcription factor 2 Tcf2 2.04 NM_013103
Transcription factor 4 Tcf4 2.13 BF398507
Cell proliferation
Alpha-2-glycoprotein 1, zinc Azgp1 2.08 NM_012826
Calcium/calmodulin-dependent protein kinase II beta subunit Camk2b 1.83 NM_021739
Chemokine (C-X-C motif) ligand 10 Cxcl10 1.84 NM_139089
Insulin receptor substrate 2 Irs2 2.28 CB547418
Neutrophil cytosolic factor 1 Ncf1 2.64 NM_053734
Platelet-derived growth factor, C polypeptide Pdgfc 1.94 NM_031317
Upregulated by 1,25-dihydroxyvitamin D-3 Txnip 2.58 CB548021
Response to stress
Aryl hydrocarbon receptor Ahr 1.95 NM_013149
Chemokine (C-C motif) ligand 5 Ccl5 2.05 NM_031116
Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 1.94 NM_133550
Heat shock 27 kD protein family, member 7 Hspb7 2.20 CB606395
Heat shock factor 2 Hsf2 2.43 NM_031694
Myeloid cell leukemia sequence 1 Mcl1 1.84 BF553322
Nitric oxide synthase 2, inducible Nos2 1.83 NM_012611
Oxidized low density lipoprotein (lectin-like) receptor 1 Oldlr1 2.09 NM_133306
Peptidoglycan recognition protein 1 Pglyrp1 1.99 NM_053373
Thioredoxin reductase 1 Txnrd1 2.24 NM_031614
Signal transduction
5-hydroxytryptamine (serotonin) receptor 2A Htr2a 1.96 NM_017254
Activin receptor interacting protein 1 Acvrip1 2.24 NM_053621
Agouti A 2.18 NM_052979
Angiotensin receptor-like 1 Agtrl1 2.06 NM_031349
Growth factor receptor bound protein 2-associated protein 2 Gab2 1.92 NM_053417
Growth hormone releasing hormone Ghrh 1.98 NM_031577
Guanylate cyclase 1, soluble, beta 2 Gucy1b2 1.91 NM_012770
MAS-related G-protein coupled receptor, member G Mrgprg 2.80 CB545776
Mcf.2 transforming sequence-like Mcf2l 2.24 NM_053951
Membrane-spanning 4-domains, subfamily A, member 2 Ms4a2 1.88 NM_012845Page 5 of 12
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BMC Genomics 2007, 8:453 http://www.biomedcentral.com/1471-2164/8/453Protein kinase, cAMP-dependent, regulatory, type 2, alpha Prkar2a 2.01 AW919085
Rho guanine nucleotide exchange factor (GEF) 1 Arhgef1 2.09 NM_021694
Rho guanine nucleotide exchange factor 7 Arhgef7 1.88 CA512056
Cell-cell signaling
4-aminobutyrate aminotransferase Abat 1.85 BF393840
Discs, large (Drosophila) homolog-associated protein 2 Dlgap2 2.38 NM_053901
Gap junction membrane channel protein beta 5 Gjb5 1.89 NM_019241
Metabolism
11-beta-hydroxysteroid dehydrogenase 11-HSDIB 1.93 M77835.1
Acetyl-coenzyme A carboxylase alpha Acaca 2.09 NM_022193
Aldehyde oxidase 1 Aox1 2.39 NM_019363
Alpha 1,2-fucosyltransferase C gene Ftc 1.98 NM_020541
Apolipoprotein A-I Apoa1 2.50 NM_012738
Cholinergic receptor, muscarinic 3 Chrm3 2.08 NM_012527
Diazepam binding inhibitor-like 5 Dbil5 1.84 NM_021596
Elastase 2 Ela2 2.03 NM_012553
Fatty acid binding protein 3 Fabp3 2.14 NM_024162
FK506 binding protein 1b Fkbp1b 2.01 NM_022675
Glucosidase, alpha; acid (glycogen storage disease type II) Gaa 2.30 CB544857
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 1
Hsd3b1 1.94 AI060276
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 5 Ndufa5 2.03 BQ210630
Nicotinamide nucleotide transhydrogenase Nnt 1.95 CB544867
Peptide/histidine transporter PHT2 Slc15a3 1.92 NM_139341
Phosphate cytidylyltransferase 1, choline, alpha isoform Pcyt1a 2.49 NM_078622
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 Plod1 2.43 AA944202
Proteasome (prosome, macropain) 26S subunit, ATPase 3 Psmc3 1.90 NM_031595
Protein kinase C, gamma Prkcc 2.04 NM_012628
Serine/threonine kinase 2 Slk 1.89 AA955942
Small glutamine rich protein with tetratricopeptide repeats 2 Sgtb 2.03 CB545680
Succinate-semialdehyde dehydrogenase 1.93 L34821.1
Transmembrane protease, serine 8 (intestinal) Tmprss8 1.88 CB544856
Valosin-containing protein Vcp 2.44 CB546610
Transport
Adducin 1 (alpha) Add1 2.65 NM_016990
Apolipoprotein A-V Apoa5 2.00 NM_080576
Cholinergic receptor, nicotinic, alpha polypept. 1 Chrna1 1.88 NM_024485
CUB and zona pellucida-like domains 1 Cuzd1 2.25 NM_054005
Epidermal growth factor Egf 2.05 NM_012842
Gamma-aminobutyric acid A receptor, gamma 2 Gabrg2 1.87 AW523484
Glutamate receptor, ionotropic, kainate 4 Grik4 2.00 NM_012572
Glutamate receptor, ionotropic, NMDA2D Grin2d 1.91 NM_022797
Olfactory receptor 226 Olfr41 1.90 NM_031710
Potassium inwardly-rectifying channel, subfamily J, member 6 Kcnj6 1.84 NM_013192
RAB10, member RAS oncogene family Rab10 2.33 CB547865
Rabaptin, RAB GTPase binding effector protein 2 Rabep2 2.07 NM_058213
Sodium channel, voltage-gated, type II, beta polypeptide Scn2b 2.01 NM_012877
Solute carrier family 12, member 4 Slc12a4 2.38 BI295055
Solute carrier family 13, member 1 Slc13a1 1.89 AA818620
Synaptotagmin 8 Syt8 2.48 NM_053325
Cell organization
Adaptor-related protein complex 3, mu 2 subunit Ap3m2 2.00 NM_133305
ATP-dependent, RNA helicase Ddx52 1.84 NM_053525
Bassoon Bsn 1.94 NM_019146
Cadherin-8 Cdh8 2.42 AB010436.1
Integrin alpha 5 Itga5 1.94 CB546515
Myoglobin Mb 2.13 AA964911
Synaptotagmin 1 Syt1 2.14 AW141251
Trans-golgi network protein 1 Tgoln2 1.93 NM_138840
Other
Alpha-1-B glycoprotein A1bg 1.84 NM_022258




CDC91 cell division cycle 91-like 1 (S.cerevisiae) Cdc91l1 2.57 BQ193826
Table 2: Microarrays results (Continued)Page 6 of 12
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Glycoprotein, synaptic 2 Gpsn2 1.87
Guanylate cyclase activator 2A Guca2a 2.43 NM_013118
Heparan sulfate proteoglycan, perlecan domain I Cd44 2.20 U56859.1
Heat-responsive protein 12 Hrsp12 1.92 NM_031714
Insulin-like 6 Insl6 1.95 NM_022583
Kinesin-related protein KRP5 KRP5 1.99 AF035954.1
Luteinizing hormone beta Lhb 1.99 U25802
Ly6-C antigen Ly6c 2.02 NM_020103
Mitochondrial capsule selenoprotein Mcsp 2.46 NM_031536
Neural visinin-like Ca2+-binding protein type 2 Nvjp2 1.95 NM_017357
NIMA related kinase 2 Nek2 1.86 AF352021.1
Nuclear GTPase PIKE PIKE 1.84 NM_023026
Nucleoporin 98 Nup98 2.18 NM_031074
Oxytocin receptor Oxtr 2.11 AF380129.1
Olfactory-specific cytochrome P-450 P-450olf1 2.03 M33296.1
Potassium channel tetramerisation domain containing 13 Kctd13 2.33 AI045333
Proline-rich protein 15 Prp15 2.24 NM_012632
RAB8A, member RAS oncogene family Mel 2.12 BC087584
Regucalcin gene promotor region related protein Rgpr 2.05 AB060653
Ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) Rnasel 2.05 CB546885
Ring finger protein 38 Oip1 1.85 NM_134467
Serine protease inhibitor Spin2b 2.67 NM_012657
Signal recognition particle 54 kDa Srp54 1.97 BC079117
Sodium-cotransporter rkST1 rkST1 1.95 U47673.1
Synaptosomal-associated protein, 91 kDa homolog (mouse) Snap91 2.23 NM_031728
Telomerase catalytic subunit 2.61 AF247818.1
Titin Ttn 1.88 AF059344.1
Ubiquitin specific protease 11 Usp11 2.51 CB546595
Zinc finger protein 14 (DZF14) DZF14 1.87 U78142.1
Zinc finger, DHHC domain containing 7 Zdhhc7 1.83 AY040615
Down-regulated genes
Glutamate decarboxylase 1 Gad1 -3.65 NM_017007
35 days
Glutamate decarboxylase 1 Gad1 -2.69 NM_017007
50 days
Up-regulated genes
Carboxylesterase 1 Ces1 1.79 NM_031565
Carboxypeptidase A1 (pancreatic) Cpa1 1.74 NM_016998
Corticotropin releasing hormone 1 Crhr1 1.79 NM_030999
Ectonucleotide pyrophosphatase/phosphodiesterase 5 Enpp5 2.00 CB544850
Glucagon receptor, transcript variant 2 Gcgr 1.74 NM_172091
Glycoprotein 2 (zymogen granule membrane) Gp2 1.80 NM_134418
Malic enzyme 1 Me1 1.74 NM_012600
Nuclear receptor subfamily 4, group A, member 1 Nr4a1 2.06 NM_024388
Transcription elongation factor A2 Tcea2 1.75 NM_057098
Tryptophan hydroxylase Tph 1.93 X53501.1
Down-regulated genes
Actinin alpha 3 Actn3 -2.76 NM_133424
Creatine kinase, muscle form Ckm -3.64 NM_012530
Glutamate decarboxylase 1 Gad1 -2.69 NM_017007
Myosin, light polypeptide 2 Myl2 -4.90 NM_012605
Parvalbumin (calcium binding protein) Pvalb -2.38 NM_022499
Titin Ttn -2.51 AF059344.1
Troponin I, skeletal, fast 2 Tnni2 -2.46 NM_017185
Troponin-c Tnnc2 -4.77 AI639532
100 days
Translin Tsn 2.40 NM_021762
Whey acidic protein Wap 2.87 NM_053751
List of known genes down- and up-regulated in mammary glands of BBP treated rats at 21, 35, 50 and 100 days. Average fold change related to 
control mammary glands is indicated. Up-regulated genes at 21 days have been sorted by function according to level 4 of Gene Ontology.
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[20]. Exposure to BBP in other phases of development
induced alterations in the onset of puberty. Ashby et al.
reported advanced vaginal opening by 1.1 days without
modifications on uterine weight in rats by effect of prena-
tal plus prepubertal exposure to BBP, although the
authors considered that this result could be related to the
variability of the observation or, more interestingly, to an
increase in the weight of the BBP treated animals [21]. In
two generational studies, Aso et al. reported changes in
anogenital distance of female offspring of rats treated with
more than 100 mg/kg [22].
Little is known on the effects of BBP on mammary gland,
another target of sexual maturity, and the present work
indicates that BBP did not induce significant changes in
the morphology of that gland, but changed the prolifera-
tive index of TEB by 35 days and in Lob1 at 35, 50 and 100
days. Although these modifications are subtle, we cannot
rule out that they may have an effect if the mammary
gland susceptibility to carcinogenesis, since TEB are the
most susceptible epithelial structures to malignant trans-
formation [23] and prevention of chemically-induced
mammary carcinomas is accompanied by inhibition of
cell proliferation [13,14]. Changes in the proliferative
index of Lob1 in BBP exposed animals in comparison to
control group can be associated with subtle alterations in
mammary development. The proliferation of Lob1 is
related to the differentiation of these structures to lobules
type 2 [23]. Control group had the highest proliferative
index in Lob1 by 50 days, concomitantly with the highest
number of Lob1, at the age of profound changes that the
mammary gland faces as a result of an intense hormonal
activity [13,14]. BBP exposed animals had the maximum
mitotic index in Lob1 by 35 days, decreasing by 50 days.
In addition, the reduction of proliferation in Lob1 of BBP
group by 100 days was not as important as in control
group. The significant changes observed are compatible
with slight changes in the timing of the breast tissue devel-
opment by effect of BBP exposure.
We are the first to report that neonatal/prepubertal expo-
sure to BBP induced modifications in the gene expression
of the mammary tissue. Whereas the full relevance of
these findings requires tumorigenesis studies, the charac-
terization of the genomic signature of the mammary
gland could be used as a predictor of the susceptibility to
carcinogenesis. This statement is based on previous works
in which changes in susceptibility to DMBA-induced car-
cinogenesis are accompanied by the induction of a spe-
cific genomic profile [13,14,24]. Neonatal/prepubertal
exposure to BBP induced changes in the genomic profile
of the mammary gland, mainly at the end of treatment
(21 days) with a focus on genes involved in cell prolifera-
tion/differentiation, communication and signal transduc-
tion. Some of those genes related to differentiation were
validated by real time RT-PCR, as Fabp3 and Wt1. Fabp3
belongs to the family of the fatty acid binding proteins,
which have a role in fatty acid transport or metabolism.
This member, however, is considered an identical homo-
logue of the mammary-derived growth inhibitor (MDGI),
with a role in the differentiation of the mammary gland
[25]. MDGI is a suppressor of tumor growth and an inhib-
itor of tumor cell proliferation [26]. We have previously
observed that this gene is up-regulated in the most differ-
entiated structures of the mammary gland (lobules type 4)
and silenced in breast cancer progression [27]. Another
gene found significantly up-regulated by 21 days is Wt1,
which has also been related to development of the mam-
mary gland although its specific function is not well
known [28,29]. This gene is essential for the development
of the urogenital system but its role in the breast tissue is
controversial. Wt1 presents a developmental pattern of
expression in normal mammary gland, and changes
observed in cell lines and tumors may be indicative of
breast-tumor-related perturbations of Wt1 expression
[29]. Cadherin 8 (cdh8), also found up-regulated in the
exposed animals, is an adhesion molecule with an impor-
tant role in brain and kidney development and differenti-
ation [30,31]. We have also observed transitional changes
in the expression of these three genes by effect of prepu-
bertal exposure to other endocrine disruptor, bisphenol A
[32]. Moreover, we also observed changes in the expres-
sion of Fabp3 when this endocrine disruptor was admin-
istered in utero. Thus, the exposure during the prenatal
Comparative expression analyses of selected genesFigure 3
Comparative expression analyses of selected genes. 
Gene expression analyses by real time RT-PCR in compari-
son with results from microarrays. Grey bars represent 
results obtained in the microarrays, black bars represent 
results obtained in the real time RT-PCR. Results show the 
mean fold expression of the treated group related to control 
group. The functional categories significantly over-repre-
sented are indicated (21 days). *: significant differences com-
pared to control group (p < 0.05).Page 8 of 12
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regulation of Fabp3 depending on the age tested, suggest-
ing a "shift" in the normal development of the mammary
gland, while prepubertal exposure to this endocrine dis-
ruptor induced a transient up-regulation just at the end of
the treatment [32]. Fabp3 mRNA has also been reported
as sensitive to the action of other hormone interfering
agents, since the antiestrogens tamoxifen and ICI up-reg-
ulate its expression by stabilization of the mRNA [33].
These evidences suggest that genes related to differentia-
tion of the mammary gland can be very sensitive to the
effects of several compounds that may interfere with hor-
monal action, suggesting that, even if the effects are not
strong enough to modify mammary histoarchitecture,
they may change the molecular milieu of the gland.
By 21 days of age we also found a moderate increase in the
expression of the transcription factors Foxg1, Hfh1 and
Ahr. Foxg1 and Hfh1 have a role in the development and
differentiation of several tissues, but to date their function
in the mammary gland is unknown [34,35]. The aryl
hydrocarbon receptor (Ahr) belongs to the PAS (per-arnt-
sim) family of transcription factors. PAS proteins control
important physiological processes, as toxicant metabo-
lism, circadian rhythms and hormone signaling [36]. We
have previously reported a role of Ahr in mammary differ-
entiation, as an increased expression in primary cultures
of Lob3 from parous women compared to primary cul-
tures of Lob1 from nulliparous women breast was
observed [37]. Ahr is known to interact with signaling
pathways that are mediated by estrogen receptor and
other hormone receptors. The mechanisms of Ahr-estro-
gen receptor crosstalk seem to be complex, and recent
studies suggest direct activation of estrogen-regulated tar-
get genes by Ahr [38]. Thus, our results suggest that the
increase in Ahr could be one of the mechanisms by which
BBP treatment exerts the observed transitory effects at 21
days.
We also observed and validated down-regulation of Gad1
by 35 and 50 days of age. This gene codes for the protein
Gad67, which catalyzes the production of the neurotrans-
mitter GABA. Gad1 can be regulated by estrogens in rat
brain [39,40], and expression changes in discrete regions
of the rostral preoptic area during estrous cycle and with
age has been described [41]. In addition, Gad1 has also a
role in the control of puberty in nonhuman primates [42].
Modifications in the expression of Gad1 has been investi-
gated in relation to some brain disorders, since Gad1
mRNA decreased in prefrontal cortex and other brain
areas of schizophrenia and bipolar disorder patients with
psychosis [43]. Experiments in rats have found down-
modulation of Gad1 accompanied by hypermethylation
of Gad1 promoter very likely mediated by the overexpres-
sion of DNA methyltransferase 1 in cortical GABAergic
interneurons [44]. Thus, we can consider the possibility
that the observed changes in Gad1 are due to an effect of
BBP on the methylation of Gad1 promoter. BBP has also
shown an effect on the methylation status of other genes
in vitro, as the reported demethylation of ERα promoter-
associated CpG islands in MCF-7 cells [45]. The GABA-
ergic system has been involved in hormonal regulation
and pathogenesis of breast cancer, since human and
mouse tumors have shown higher GABA level and GAD
activity than normal tissue [46]. Hence, although prepu-
bertal exposure to BBP seems to have mainly a transitory
effect on the genomic profile of the mammary gland, we
cannot discard that subtle changes in the gland may have
an effect later in life. Finally, very few genes were regulated
by BBP exposure in the oldest age tested (100 days).
Conclusion
In summary, neonatal/prepubertal exposure to BBP had a
transitory effect by increasing the relative uterine weight
only at the end of exposure. This compound also changed
the gene expression profile of the mammary gland mainly
at the same age, although long-term subtle alterations can
not be ruled out.
Methods
Animals and experimental design
Animals were housed in 12 hour light/dark cycle and con-
trolled temperature in the University of Alabama at Bir-
mingham animal facility. Pregnant Sprague Dawley CD
rats (Charles River, Raleigh NC) were bred and main-
tained on phytoestrogen-free AIN-93G diet (Harlan Tek-
lad, Madison WI). After parturition, litters were adjusted
to 10 offspring per mother, and the lactating dams (10
dams per group) were gavaged with 500 mg BBP/kg body
weight or an equivalent volume of sesame oil on days 2–
20 (Mondays-Fridays only). We used a stock solution of
200 mg BBP/ml sesame oil, and dams were gastric intu-
bated with 2,5 µl BBP/g BW (0.5 ml for a dam of 200 g)
each day, preferable each late afternoon. The offspring
were weaned at day 21 and continued on AIN-93G diet
until day 70 where they were switched to AIN-93M diet.
Vaginal opening was assessed as an index of maturation
and body weight was recorded from a minimum of 27
female offsprings/group.
Female offspring were processed at 21, 35 ± 1, 50 ± 1 and
100 ± 2 days. For the cycling animals (the latter 3 ages), all
females were killed in the estrus phase of the estrous cycle.
The day of euthanasia the animals were anesthetized with
ketamine (10 mg/100 g)/xylazine (1.5 mg/100 g), the
fourth mammary glands were rapidly dissected and frozen
for microarrays analysis (1 female offspring from each lit-
ter at each time point). Transsection of the aorta was per-
formed after the tissues were properly collected. From
another set of females from each litter, mammary glandsPage 9 of 12
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differentiation analysis, and the contralateral mammary
glands were paraffin-blocked for cell proliferations stud-
ies. Ten glands representing all litters per group at each
time point were used for each of the molecular, morpho-
logical and proliferation analyses. Uterine weight was also
recorded at day of sacrifice and uterine weight/body
weight ratios were calculated for each animal. Differences
among groups were analyzed using Tukey's Test (p <
0.05). All animal studies were conducted in accordance
with the University of Alabama at Birmingham Guide-
lines for Animal Use and Care.
Mammary whole mounts analysis
The excised mammary glands were fixed in 10% neutral-
buffered formalin followed by de-fatting in acetone. The
tissues were stained in alum carmine overnight and dehy-
drated in a series of graded ethanol. The glands were
cleared in xylene and coverslipped with mounting media.
Analysis of mammary epithelial structures (terminal end
buds -TEBs-, terminal ducts -TDs-, alveolar buds -ABs- and
lobules type 1 -Lob1-) was made through visual evalua-
tion and computer-assisted image analysis using Meta-
Morph Imaging System (Universal Imaging Corporation,
Downingtown PA). The outer 5-mm margin of the mam-
mary whole mount was examined by light microscopy
using the criteria of Russo and Russo [23]. This area repre-
sents the location of most actively proliferating TEB struc-
tures of the mammary gland for a young virgin rat [47],
The total number of each epithelial structure was deter-
mined under an Olympus microscope using a 40× magni-
fication objective. The collected data were analyzed using
two-tailed unpaired t-tests.
Proliferative index analysis
Two hours before euthanasia animals were weighed and
injected i.p. with 100 mg bromodeoxyuridine (BrdU,
Sigma, St. Louis, MO) per kg body weight. The fourth
abdominal mammary glands were excised and fixed in
10% neutral-buffered formalin, embedded in paraffin
and sectioned at 4 µm thickness. Tissue sections were
mounted on positively charged slides and immunocyto-
chemically reacted with anti-BrdU monoclonal antibody
(BioGenex, San Ramon, CA) using an automatic slide
stainer (BioGenex). The incorporation of BrdU in the
mammary glands was visualized using the streptavidin-
biotin labeling system with 3, 3'-diaminobenzidine
(DAB) as a color reaction substrate (BioGenex). The pro-
liferative index was determined quantitatively using an
Olympus BX40 microscope (60× magnification objective)
as the percentage of DAB positive cells within each specific
epithelial structure, i.e., TEBs, TD and ducts, ABs and
Lob1. All cells in each structure were counted blinded to
the groups. A minimum of 1,000 cells per tissue sample
was examined. Data from different groups were analyzed
by unpaired t-tests.
Characterization of the genomic profile
Gene expression profile was determined from total RNA
using Agilent 60-mer oligo-microarrays slides containing
22,000 sequences. RNAs from the mammary glands were
extracted with the RNeasy Mini Kit (Qiagen Inc., Valencia,
CA). The quantity and purity of each RNA sample was
determined from the 260- and 280-nm absorbance, and
its integrity was determined (2100 BioAnalyzer; Agilent
Technologies Inc., Palo Alto, CA). Only high quality RNA,
with absorbance 260/280 greater than 1.8 and RNA integ-
rity number (RIN) greater than 8 were considered for fur-
ther analysis. 250 ng of pooled RNA from two-three
different mammary glands were fluorescent labeled with
Agilent Low Input RNA Fluorescent Linear Amplification
Kit (Agilent Technologies) in the presence of Cy3-dCTP or
Cy5-dCTP (Perkin Elmer, Wellesley, MA), and purified
using RNeasy Mini Kit (Qiagen Inc., Valencia, CA).
Four separate experiments, each including two to three
mammary gland cRNA pool were performed at each time
point studied. 750 ng of Cy3 labeled control cRNA and
750 ng of Cy5 labeled BBP group cRNA were used to
hybridize each slide at 60°C for 18 hours. Slides were
washed and fluorescence images were captured with a
laser scanner (Agilent Technologies). The obtained images
were analyzed with Feature extraction software (Agilent
Technologies) to verify the quality of the hybridization by
the report of the outlier data.
Feature extraction software automatically flagged non-
uniform features and population outliers, considering
acceptable outlier numbers lower than 5% of total feature
number on the array. Intensity of each fluorescent signal
was quantified by ImaGene 5.6 software (BioDiscovery
Inc., El Segundo, CA) and statistically analyzed using Gen-
eSight 4.1.6 software (BioDiscovery) with Lowess normal-
ization considering the arrays per group as replicates. We
determined the genes with ≥ 1.4-fold differences by confi-
dence analyses at p < 0.05 following manufacturer's rec-
ommendations. We performed functional analysis of the
genes obtained as modulated by BBP exposure using PAN-
THER (Protein ANalysis THrough Evolutionary Relation-
ships). Genes were annotated according to known
biological process, molecular function and biological
pathways. The number of genes in each category was sta-
tistically compared to NCBI: R. norvegicus genes database
to look for under- and over-represented functional catego-
ries using the binomial test [48] and the Bonferroni cor-
rection for multiple testing. Genes with known function
were also classified using Gene Ontology database.Page 10 of 12
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Several genes found differentially expressed in the mam-
mary glands of rats exposed to BBP were chosen for con-
firmation by real-time reverse transcription PCR (RT-
PCR). Beta-actin was used as a control. All RT-PCR reac-
tions were performed on the ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA)
using the fluorescent TaqMan methodology (TaqMan
One Step RT-PCR Master Mix Reagents, Applied Bio-
sytems) following manufacturer's protocol. 100 ng of
total RNA in 50 µl of final volume was reverse-transcribed
(30 min at 48°C) and amplified following 1 cycle of 10
min at 95°C, and 40 cycles of 15 s denaturation at 95°C
and 60 s annealing at 60°C. Each gene was normalized to
beta-actin and data was analyzed using two-tailed
unpaired t-test.
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